The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development
Abstract
The transcription factor NRF2 (nuclear factor erythroid 2-related factor 2) triggers the first line of homeostatic responses against a plethora of environmental or endogenous deviations in redox metabolism, proteostasis, inflammation, etc. Therefore, pharmacological activation of NRF2 is a promising therapeutic approach for several chronic diseases that are underlined by oxidative stress and inflammation, such as neurodegenerative, cardiovascular, and metabolic diseases. A particular case is cancer, where NRF2 confers a survival advantage to constituted tumors, and therefore, NRF2 inhibition is desired. This review describes the electrophilic and nonelectrophilic NRF2 activators with clinical projection in various chronic diseases. We also analyze the status of NRF2 inhibitors, which at this time provide proof of concept for blocking NRF2 activity in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Domain structures of NRF2 and KEAP1. (a) Domain structure of NRF2. NRF2 possesses six highly conserved domains called NRF2-ECH homology (Neh) domains [167]. The functional role of each Neh domain is specified. Within the Neh2 domain, the low-affinity (DLG) and high-affinity (ETGE) binding domains to KEAP1 are zoomed in. (b) Domain structure of a KEAP1 monomer showing the position of cysteine residues. The N-terminal BTB (bric-a-brac, tramtrack, broad complex) domain participates in homodimerization and binding to CUL3/RBX1. The C-terminal region, DGR (double glycine repeat) domain, contains a double glycine repeat called Kelch repeat that binds NRF2-Neh2 domain. The intervening region (IVR/LR) connects BTB and DGR domains and is particularly rich in redox-sensitive cysteine residues. Red and blue cysteine residues in KEAP1 are the most relevant for electrophile reactivity. This figure has been modified and extended from [168] to highlight the degradation domains in NRF2 and the cysteines of KEAP1.](/paper-figures/eda0f18d5c5548b48554e482847451a0/activators-and-inhibitors-of-nrf2-a-review-of-their-potential-for-clinical-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activation of NRF2 is now a target for longevity researchers as its function offers therapeutic potential for numerous diseases that involve oxidative stress or inflammation including neurodegenerative, metabolic, and cardiovascular diseases.”
From Three Tiers to biological escape velocity: The quest to outwit aging (2022) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“The nuclear factor erythroid 2‐related factor 2 (NRF2) pathway has also become a target to resist aging, with its activity functioning as the first responder against an array of endogenous divergent facets such as redox metabolism, inflammation, and proteostasis. 19”
From Three Tiers to biological escape velocity: The quest to outwit aging (2022) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of nrf2 in oxidative stress and toxicity
Ma, Q. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140320 · Cited by 4,903
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634
Jain, A., Lamark, T., Sjøttem, E., Bowitz Larsen, K., Atesoh Awuh, J., Øvervatn, A., McMahon, M., Hayes, J. D., & Johansen, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.118976 · Cited by 1,472
Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, A., Yamamoto, M., Kensler, T. W., & Talalay, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307301101 · Cited by 986
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Small Molecule Modulators of Keap1‐ Nrf2‐ ARE Pathway as Potential Preventive and Therapeutic Agents
Magesh, S., Chen, Y., & Hu, L. (2012) · Medicinal Research Reviews · doi:10.1002/med.21257 · Cited by 760
Tong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759
Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., & Zhang, D. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014275108 · Cited by 673
Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling
Lo, S., Li, X., Henzl, M. T., Beamer, L. J., & Hannink, M. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601243 · Cited by 604
A Phase II Trial of Tideglusib in Alzheimer's Disease
Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536
Davies, T. G., Wixted, W. E., Coyle, J. E., Griffiths-Jones, C., Hearn, K., McMenamin, R., Norton, D., Rich, S. J., Richardson, C., Saxty, G., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00228 · Cited by 322
Characterizations of Three Major Cysteine Sensors of Keap1 in Stress Response
Saito, R., Suzuki, T., Hiramoto, K., Asami, S., Naganuma, E., Suda, H., Iso, T., Yamamoto, H., Morita, M., Baird, L., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00868-15 · Cited by 294
Keap Calm, and Carry on Covalently
Wilson, A. J., Kerns, J. K., Callahan, J. F., & Moody, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400224q · Cited by 171
Hancock, R., Schaap, M., Pfister, H., & Wells, G. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob40249e · Cited by 91
Enzastaurin: A lesson in drug development
Bourhill, T., Narendran, A., & Johnston, R. N. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.003 · Cited by 55
Research works printed but not linked: 149
- 10.1016/j.tibs.2014.02.002 · DOI
- 10.1080/15548627.2016.1208889 · DOI · Paper page
- 10.1016/j.redox.2017.01.006 · DOI
- 10.1007/s40495-016-0053-2 · DOI
- 10.1016/j.redox.2015.07.003 · DOI
- 10.1038/s41573-018-0008-x · DOI
- 10.1124/pr.117.014753 · DOI · Paper page
- 10.1016/j.ccell.2018.03.022 · DOI · Paper page
- 10.1074/jbc.M403061200 · DOI
- 10.1016/j.abb.2004.10.012 · DOI
- 10.1128/MCB.00753-07 · DOI
- 10.1016/j.tips.2013.04.005 · DOI · Paper page
- 10.1016/j.abb.2016.10.010 · DOI
- 10.1021/tx800226m · DOI
- 10.1038/nrn2870 · DOI
- 10.1038/35017574 · DOI
- 10.1016/j.freeradbiomed.2015.04.029 · DOI
- 10.1038/onc.2012.388 · DOI · Paper page
- 10.1101/gad.238246.114 · DOI
- 10.1074/jbc.M412081200 · DOI
- 10.1128/MCB.22.9.2883-2892.2002 · DOI
- 10.1158/0008-5472.CAN-14-1439 · DOI · Paper page
- 10.1038/nature10189 · DOI · Paper page
- 10.1182/blood-2012-04-422121 · DOI · Paper page
- 10.1182/blood-2009-04-214817 · DOI
- 10.1007/s10549-011-1604-1 · DOI
- 10.1016/j.bbrc.2018.10.182 · DOI
- 10.1155/2018/2492063 · DOI
- 10.1016/j.cbpa.2010.12.009 · DOI
- 10.1016/j.freeradbiomed.2013.07.022 · DOI
- 10.1021/acs.jmedchem.5b01292 · DOI
- 10.1074/jbc.M110.190710 · DOI · Paper page
- 10.1074/jbc.M109.051714 · DOI
- 10.1042/bj20031049 · DOI
- 10.1128/MCB.01704-07 · DOI
- 10.1073/pnas.1305687110 · DOI
- 10.1371/journal.pone.0098896 · DOI
- 10.1128/MCB.00389-16 · DOI
- 10.1038/s41598-018-26269-9 · DOI
- 10.1073/pnas.0500815102 · DOI
- 10.1124/pr.111.004846 · DOI
- 10.1089/ars.2012.5118 · DOI
- 10.1002/acn3.660 · DOI
- 10.1016/j.diabres.2018.02.021 · DOI
- 2015, Cochrane Database of Systematic Reviews, 4, article cd011076
- 10.1111/j.1468-1331.2006.01292.x · DOI
- 10.1056/NEJMoa1114287 · DOI
- 10.1056/NEJMoa1206328 · DOI
- 10.1159/000017903 · DOI
- 10.3389/fneur.2018.00005 · DOI
- 10.1212/NXI.0000000000000340 · DOI
- 10.4049/jimmunol.1601649 · DOI
- 10.1002/acn3.411 · DOI
- 10.1093/brain/awq386 · DOI · Paper page
- 10.1007/s00403-013-1332-y · DOI
- 10.1080/13543776.2017.1325464 · DOI
- 10.1016/j.msard.2018.04.016 · DOI
- 10.1038/nrc1076 · DOI
- 10.1152/ajpgi.90321.2008 · DOI
- 10.1089/ars.2009.2903 · DOI
- 10.1371/journal.pone.0204853 · DOI
- 10.1016/j.diabres.2012.01.009 · DOI
- 10.1126/scitranslmed.aah4477 · DOI
- 10.1016/j.brainres.2010.04.036 · DOI
- 10.1016/j.neulet.2005.09.065 · DOI
- 10.1007/s12272-009-1124-2 · DOI
- 10.3109/13506129.2012.751367 · DOI
- 10.1124/jpet.106.110866 · DOI
- 10.1089/ars.2010.3731 · DOI
- 10.1155/2013/415078 · DOI
- 10.1155/2016/7857186 · DOI
- 10.1111/bph.13025 · DOI
- 10.1111/j.2042-7158.1997.tb06761.x · DOI
- 10.1021/acs.jafc.6b00053 · DOI
- 10.1002/mnfr.201200131 · DOI
- 10.1016/j.jnutbio.2013.09.013 · DOI
- 10.1007/s00018-008-7452-4 · DOI
- 10.1042/bj20021619 · DOI
- 10.1124/jpet.118.254755 · DOI
- 10.1155/2017/3924912 · DOI
- 10.1038/aps.2016.108 · DOI
- 10.1074/jbc.M116.751909 · DOI
- 10.1038/nature25986 · DOI · Paper page
- 10.1016/j.chembiol.2009.12.013 · DOI
- 10.1006/bbrc.2000.4106 · DOI
- 10.1016/j.ejphar.2017.02.044 · DOI
- 10.1074/jbc.R117.800169 · DOI
- 10.1016/j.bmcl.2015.04.019 · DOI
- 10.1177/1087057111430124 · DOI
- 10.1111/j.1747-0285.2011.01240.x · DOI
- 10.1016/j.freeradbiomed.2011.10.486 · DOI
- 10.1523/JNEUROSCI.1304-15.2015 · DOI
- 10.1016/j.ejmech.2017.10.052 · DOI
- 10.1002/cmdc.201300525 · DOI
- 10.1016/j.bmc.2013.04.019 · DOI
- 10.1021/jm5000529 · DOI
- 10.1039/C4MD00140K · DOI
- 10.1021/acs.jmedchem.8b01133 · DOI
- 10.1016/j.bmcl.2013.03.013 · DOI
- 10.1002/jbt.21693 · DOI
- 10.1021/acs.jmedchem.5b00602 · DOI
- 10.1016/j.bmcl.2015.11.082 · DOI
- 10.1016/j.abb.2017.08.003 · DOI
- 10.1111/j.1471-4159.2007.05194.x · DOI · Paper page
- 10.1016/j.arr.2014.03.008 · DOI
- 10.1016/j.canlet.2008.05.045 · DOI
- 10.1161/CIRCRESAHA.116.303613 · DOI
- 10.1016/j.ejmech.2017.11.103 · DOI
- 10.1016/j.critrevonc.2017.01.018 · DOI
- 10.1016/j.freeradbiomed.2011.11.003 · DOI
- 10.1080/13543776.2017.1259412 · DOI
- 10.1128/MCB.00180-12 · DOI
- 10.1158/0008-5472.CAN-12-4400 · DOI
- 10.1128/MCB.00248-10 · DOI
- 10.1038/ncb2021 · DOI · Paper page
- 10.1039/b804606a · DOI
- 10.1016/j.redox.2017.09.007 · DOI
- 10.1074/jbc.M500166200 · DOI · Paper page
- 10.1371/journal.pone.0101044 · DOI
- 10.1093/carcin/24.3.461 · DOI
- 10.1158/0008-5472.CAN-06-0300 · DOI
- 10.1158/1078-0432.CCR-09-3352 · DOI
- 10.1073/pnas.0806268105 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-5003 · DOI
- 10.1016/j.redox.2017.04.013 · DOI
- 10.1111/cas.13537 · DOI
- 10.1128/MCB.25.10.4150-4165.2005 · DOI
- 10.1038/onc.2017.153 · DOI
- 10.1073/pnas.0709483104 · DOI
- 10.1158/0008-5472.CAN-12-3386 · DOI · Paper page
- 10.1002/mc.22609 · DOI
- 10.1074/mcp.M115.055509 · DOI
- 10.1016/j.freeradbiomed.2016.09.010 · DOI · Paper page
- 10.1016/j.freeradbiomed.2011.03.008 · DOI
- 10.1002/mc.21921 · DOI
- 10.3109/15376516.2013.843111 · DOI
- 10.3390/toxins6010371 · DOI
- 10.1038/onc.2012.493 · DOI
- 10.1016/j.phymed.2015.05.007 · DOI
- 10.1016/j.exphem.2004.01.007 · DOI
- 10.1021/acschembio.6b00651 · DOI
- 10.1016/j.freeradbiomed.2016.12.041 · DOI
- 10.1021/acschembio.5b00448 · DOI
- 10.18632/oncotarget.13825 · DOI
- 10.1021/ml300041g · DOI
- 10.1021/acs.jmedchem.5b00185 · DOI
- 10.1124/jpet.117.241794 · DOI
- 10.1039/C3MD00240C · DOI
- 10.1111/j.1365-2443.2010.01473.x · DOI · Paper page
Cited by
Sorted by citations
Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy
Forman, H. J., & Zhang, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00233-1 · Cited by 2,900
Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease
Ngo, V., & Duennwald, M. L. (2022) · Antioxidants · doi:10.3390/antiox11122345 · Cited by 1,130
Oxidative stress: The core pathogenesis and mechanism of Alzheimer’s disease
Bai, R., Guo, J., Ye, X.-Y., Xie, Y., & Xie, T. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101619 · Cited by 813
The Keap1-Nrf2 System: A Mediator between Oxidative Stress and Aging
Yu, C., & Xiao, J.-H. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6635460 · Cited by 537
NRF2 as a Therapeutic Target in Neurodegenerative Diseases
Brandes, M. S., & Gray, N. E. (2020) · ASN Neuro · doi:10.1177/1759091419899782 · Cited by 297
Metadata
- Authors
- Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., & Cuadrado, A.
- Affiliations
- Instituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, Instituto de Investigación Sanitaria La Paz (IdiPaz) and Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain
- Victor Babes National Institute of Pathology, Bucharest, Romania
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2019-07-14
- Volume
- 2019
- Pages
- 1-20
- ISSN
- 1942-0900
- 1942-0994
- PMC
- PMC6664516
- Cited by
- 413
- References
- 16
- Language
- en
- Funders
- European Regional Development Fund (P_37_732/2016, B2017/BMD-3827, SAF2016-76520-R)
- Autonomous Community of Madrid (P_37_732/2016, B2017/BMD-3827, SAF2016-76520-R)
- Ministerio de Economía y Competitividad (P_37_732/2016, B2017/BMD-3827, SAF2016-76520-R)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review